Related Experiment Videos
Free radical-producing enzyme, xanthine oxidase, is undetectable in human hearts
Insights
Human hearts show no detectable xanthine dehydrogenase or xanthine oxidase activity. This suggests xanthine oxidase is not a major source of O2 free radicals in ischemic hearts.
Area of Science:
- Biochemistry
- Cardiology
- Enzymology
Background:
- Xanthine dehydrogenase (XDH) and xanthine oxidase (XO) are enzymes involved in purine metabolism.
- XO can generate reactive oxygen species (ROS), contributing to oxidative stress during ischemia.
- The role of XO in the human heart, particularly during ischemia, remains unclear.
Purpose of the Study:
- To quantify the activity of xanthine dehydrogenase and xanthine oxidase in human heart samples.
- To assess the potential contribution of xanthine oxidase to oxidative stress in the ischemic human heart.
Main Methods:
- Analysis of enzyme content in four human heart samples.
- Utilized both spectrophotometric and fluorometric assays for enzyme activity determination.
Main Results:
- No detectable xanthine dehydrogenase or xanthine oxidase activity was found in any of the analyzed human heart samples.
- The upper limit for enzyme activity was determined to be less than 2.0 nU/g.
Conclusions:
- Human hearts exhibit negligible xanthine dehydrogenase/oxidase activity.
- Xanthine oxidase is unlikely to be a significant source of O2 free radicals in the ischemic human heart.
- Therapeutic strategies targeting xanthine oxidase may have limited value in treating ischemic heart conditions.
Abstract:
Samples from four human hearts were analyzed for both their xanthine dehydrogenase and xanthine oxidase content. We used the conventional spectrophotometric assay and a more sensitive fluorometric assay to determine the content of enzyme in these samples. In no case could any activity be detected. We conclude that human hearts must contain less than 2.0 nU/g of activity. This makes it unlikely that xanthine oxidase is a significant source of O2 free radicals in the ischemic human heart or that xanthine oxidase inhibitors will be of therapeutic value in that setting.